Here are the 10-K annual reports from Scilex Holding Company (SCLX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SCLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCLX filings page.
Scilex Holding Company reports on a business focused on non-opioid pain management while outlining a major shift in its balance sheet strategy toward cryptocurrencies. The company currently markets three U.S. products: ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for prophylaxis of gout flares.
Its pipeline includes SEMDEXA (SP-102) for sciatica, SP-103 for acute low back and neck pain, and SP-104 for fibromyalgia, several with FDA fast track designations or completed Phase 3 or Phase 2 studies. Scilex also plans to adopt a cryptocurrency treasury strategy emphasizing bitcoin, Ethereum, BNB, Doge and similar assets as a principal long-term reserve, using third-party custodians and advisors, and potentially raising capital specifically to expand these holdings.